Katie Greifeld

When you zoom out a bit, what are you seeing in terms of trends when it comes to what types of tests are being asked for and ordered?

Because you think about what's going on at some of your peer diagnostics companies, oncology testing has been driving just rapid growth.

So how does Quest position itself in that space?

I know that you recently

bought Haystack Oncology, for example, but is that an area where you would consider additional deals?

Bloomberg Audio Studios, podcasts, radio, news.

So, Lucas, there's a lot to dig into there.

And you mentioned, of course, the breadth of your portfolio.

But investors really, really care about the pill at this moment.

So I have to ask a little bit more about that.

You mentioned that potential 2Q launch.

Is there a possibility that this outlook that you gave this morning gets upgraded as we start to see some of the uptake there?

And so let's talk about the timeline a little bit more here.

You and I spoke a few weeks ago at the JP Morgan Healthcare Conference.

You said that you're on track for that second quarter approval.

You reiterated that timeline today, of course, pending FDA approval.

Let's talk a little bit about the FDA.

There's been some challenges there.

There's been some turnover.

Do you see that potentially impacting the timeline at all?